Skip to main content

Pelvic Floor Electrical Stimulation (PFES)

Pelvic floor electrical stimulation (PFES) is a non-invasive, non-implantable modality that delivers electrical current to activate the pudendal nerve and its branches, producing passive contraction of the pelvic floor muscles and / or inhibition of detrusor overactivity. It has been used for urinary incontinence since 1952 and is reimbursable under Medicare. The evidence supports PFES as probably better than no treatment but not clearly superior to PFMT for any indication.[1][2][4]

For PFMT — the first-line conservative therapy for SUI / UUI — see Pelvic Floor PT. For office-based tibial-nerve neuromodulation, see Percutaneous Tibial Nerve Stimulation. For implanted neuromodulation, see Sacral Neuromodulation. For incontinence behavioral therapy, see Behavioral Therapy for Urinary Incontinence.

Mechanism​

PFES operates through two distinct neurophysiologic pathways:[2][3][4]

Stress UI — neurostimulation. Stimulation of the motor-efferent fibers of the pudendal nerve elicits direct contraction of the pelvic floor muscles and striated periurethral musculature, supporting urethral closure. Proposed mechanisms: increased muscle bulk, improved active and resting urethral closure, passive exercise in patients who cannot voluntarily contract, and improved tissue vascularity.[2][1]

Urgency UI / OAB — neuromodulation. Stimulation of afferent fibers of the pudendal nerve travels to the sacral cord and reflexively inhibits parasympathetic activity at the sacral micturition center, reducing detrusor overactivity and urgency. The dominant mechanism is remodeling of neuronal reflex loops, particularly the detrusor inhibition reflex.[5][3][4]

Biofeedback function. PFES also serves as a biofeedback adjunct — by stimulating awareness, it helps patients with poor proprioception learn where and how to contract / relax the pelvic floor.[3][1]

Modalities (Non-Implanted)​

A network meta-analysis of 30 RCTs identified five principal modalities:[6]

ModalityElectrode placementMechanismTypical schedule
Intravaginal ES (IVES)Vaginal probeDirect pudendal stimulationHome or clinic; 15–20 min, 2×/d or 2–3×/wk
Intra-anal / rectal ESAnal plugDirect pudendal stimulationClinic; for men or when vaginal route is contraindicated
Surface / transcutaneous ESSuprapubic + perineal surface electrodesIndirect pudendal stimulationClinic; 20 min, 2×/wk
PTNS (percutaneous tibial)Needle 5 cm cephalad to medial malleolusRetrograde sacral plexus neuromodulationOffice; 30 min, weekly × 12 wk
TTNS (transcutaneous tibial)Surface electrodes near medial malleolusSame as PTNS, non-invasiveHome; 20–30 min, daily or 3×/wk
Extracorporeal magnetic stimulation (ExMS)Magnetic chair (no electrodes)Magnetic-field-induced pelvic-floor contractionClinic; 20 min, 2×/wk × 8 wk

Stimulation Parameters​

ParameterStress UIUrgency UI / OABMixed UI
Frequency20–50 Hz5–20 Hz (typically 10–12 Hz)20 Hz (compromise)
Pulse width200–1000 μs200–300 μs300 μs
Current intensityMaximum tolerable (up to 100 mA)Maximum tolerableMaximum tolerable
Duty cycle4–5 s on / 5–8 s off5 s on / 5 s off1:1 ratio
Session duration15–20 min20–30 min15–20 min
Frequency of sessionsDaily–every other day (home), 2–3×/wk (clinic)2×/d or 2–3×/wkEvery other day
Course8–12 wk8–12 wk8 wk

Higher frequencies (20–50 Hz) preferentially recruit fast-twitch motor fibers for sphincter closure; lower frequencies (5–20 Hz) preferentially activate afferent pathways for detrusor inhibition.[1][3][4]

PTNS-specific: 20 Hz, 200 μs, 34-gauge needle 5 cm cephalad to medial malleolus posterior to the tibia; 30 min, weekly × 12 wk → maintenance every 2–4 wk; intensity adjusted until toe flexion / fanning is observed.[9]

Efficacy by Indication​

Female stress urinary incontinence​

Cochrane 2017 (Stewart, 56 trials, n = 3,781): ES is probably better than no active or sham treatment for cure / improvement of SUI (moderate-quality). Insufficient evidence to determine superiority over PFMT; adding ES to PFMT may not add benefit.[2]

Lunardi 2025 SR / meta (7 RCTs, 411 women): ES is not superior to supervised or unsupervised PFMT for leakage reduction or QoL (very-low certainty).[10]

Goode 2003 JAMA RCT (n = 200): behavioral training alone, behavioral + PFES, and a self-help booklet. Both clinic-based programs reduced incontinence episodes by 69–72% (vs 53% booklet); adding PFES did not increase effectiveness of comprehensive behavioral therapy.[1]

Han 2022 meta (9 RCTs vs sham/no-Tx, n = 982): ES significantly improves short-term QoL (p = 0.003) and reduces leakage (p < 0.05).[11]

Urgency UI / OAB​

Cochrane 2016 (Stewart): ES is probably better than no treatment for OAB; insufficient evidence vs anticholinergics or other active treatments.[4]

Leonardo 2022 meta (low-frequency pelvic ES vs PFMT / bladder training alone): MD QoL +7.41 (p = 0.008); MD incontinence episodes −1.33 (p = 0.02); RR cure / improvement 1.46 (p = 0.003).[12]

PTNS for OAB​

Xia 2021 meta (8 RCTs, n = 420): PTNS as effective as antimuscarinics for frequency, nocturia, urge incontinence, and voided volume, with significantly fewer AEs (p = 0.0001) and lower discontinuation (p = 0.003).[13]

Yu 2024 network meta (30 RCTs): percutaneous tibial stimulation ranked the most effective non-implanted ES modality for symptom severity (SMD −1.86); intravaginal stimulation second (SMD −0.97).[6]

PTNS is now a guideline-recommended therapy for OAB, with two implantable tibial-nerve stimulators FDA-authorized.[14]

Post-radical-prostatectomy incontinence​

ES shows the most consistent benefit in the early postoperative period (1–3 mo):

  • Tang 2025 meta (10 RCTs): short-term ES (≤ 3 mo) significantly improved ICIQ-SF (MD −3.50, p < 0.05).[15]
  • Zhao 2025 network meta: ES + biofeedback ranked highest for continence recovery (SUCRA 89.9); ES + biofeedback + PFMT most effective for pad weight and ICIQ-UI SF.[16]
  • Mariotti 2009: early combined PFES + biofeedback (starting 7 d post-catheter removal) — 96.7% continence at 6 mo vs 66.7% with no treatment.[17]
  • Goode 2011 JAMA (men with persistent post-prostatectomy incontinence > 1 yr): behavioral therapy reduced incontinence, but adding biofeedback + PFES did not enhance outcomes.[18]

Fecal incontinence​

  • Cochrane (Norton 2012; 21 trials, n = 1,525): biofeedback + ES may be more effective than biofeedback alone or ES alone; participants 40% more likely to achieve full continence with biofeedback + ES.[20]
  • Mundet 2021 RCT (n = 150, FI women): all four arms (Kegel, biofeedback + Kegel, ES + Kegel, neuromodulation + Kegel) similarly improved severity / QoL; physiologic effects are treatment-specific — ES + Kegel uniquely increased resting and squeeze pressure, endurance, and shortened anal sensory-evoked-potential latency.[21]
  • ACOG PB 210 (2019) and ACG 2021: biofeedback / PFMT first-line; ES as adjunct; sacral nerve stimulation first-line surgical for refractory FI.[19][22]

Extracorporeal Magnetic Stimulation​

Completely non-invasive — patient sits fully clothed on a magnetic chair; pulsed magnetic field induces pelvic-floor contraction. No probes or electrodes.[8][23]

  • Yang 2025 meta (14 RCTs): significant ICIQ-SF improvement (SMD −0.73) and QoL (SMD −0.43); no substantial OAB or chronic-pelvic-pain effects.[8]
  • Lim 2017 sham-controlled RCT (n = 120): pulsed MS for SUI — 75% response (active) vs 21.7% (sham) at 2 mo (p < 0.05).[24]
  • Lukanović 2025 sham-controlled RCT for UUI (n = 70): ICIQ-UI SF −4.05 vs −1.19 (p < 0.05).[25]
  • Li 2026 SUI meta (17 RCTs, n = 1,389): MS improves incontinence, QoL, 1-h pad test, and MUCP — but does not significantly improve PFM strength.[26]
  • AUA / SUFU 2023: MS appears safe and may be effective for SUI; data limited by protocol heterogeneity.[7]

Home and Wearable Devices​

  • Traditional home IVES — battery-powered with vaginal probe; programmed by clinician with patient-adjustable intensity; 15 min every other day or 20 min twice daily.[1]
  • Innovo neuromuscular electrical stimulation wearable garment (NMESWG) — FDA-cleared external garment delivering ES via surface electrodes, no vaginal probe. Promising pad-weight reductions; small samples.[27]
  • Leva intravaginal sensor-based system (IVSBS) — accelerometer-based vaginal sensor with mobile-app feedback (technology-enhanced biofeedback rather than ES); superior outcomes in symptom severity and adherence vs NMESWG.[27]

Contraindications and Adverse Effects​

Contraindications:

  • Cardiac pacemaker or implanted defibrillator (intravaginal / surface ES)
  • Pregnancy
  • Active vaginal or urinary infection
  • Vaginal bleeding of unknown etiology
  • Severe pelvic organ prolapse (> grade II)
  • Complete pelvic-floor denervation
  • Reflex urinary incontinence with clear neurologic lesion (relative)
  • Metal implants in the stimulation field (magnetic stimulation)
  • Genitourinary surgery within the prior 6 months[2][4]

Adverse effects: generally mild. Cochrane meta-analyses found no significant difference in AEs between ES and sham / no treatment (RR 1.24, 95% CI 0.84–1.83).[2][4] Reported AEs:

  • Vaginal discomfort, pain, or tingling (most common)
  • Skin irritation (surface electrodes)
  • UTI
  • Mild bleeding / tenderness
  • ~ 9% experience discomfort with ES for FI[19]

Serious AEs are rare across all modalities.[2][4]

Guideline Positions​

OrganizationPosition
AUA / SUFU 2023[7]ES and magnetic stimulation are emerging therapies; data inconsistent and of poor quality; ES better than sham but unclear if equivalent to PFMT
Cochrane Overview 2022[5]ES probably better than no treatment for SUI; insufficient evidence vs PFMT; adding ES to PFMT may not add benefit
AUA / SUFU OAB GuidelinesPTNS is a third-line therapy for OAB refractory to behavioral / pharmacologic treatment
ACOG PB 210 (2019)[19]ES is an adjunct to biofeedback / PFMT for FI; biofeedback + ES may be more effective than either alone
ACG 2021[22]Sacral nerve stimulation for FI refractory to conservative therapy; PTNS evidence insufficient for FI
EAU (Male UI)PFMT + ES significantly increases short-term continence recovery after prostatectomy

Synthesis — Where PFES Fits​

  1. PFMT remains first-line conservative therapy for SUI and UUI. PFES is not clearly superior to supervised PFMT for any indication.[2][10]
  2. PFES is most useful for patients who cannot voluntarily contract the pelvic floor (extreme weakness, poor proprioception) — passive exercise + biofeedback role.[3][1]
  3. Adding PFES to PFMT is most consistently helpful in the early post-prostatectomy period (first 3 mo); long-term outcomes equalize.[15][16][28]
  4. PTNS has the strongest evidence among non-implanted modalities for OAB — efficacy comparable to antimuscarinics with significantly fewer AEs; implantable tibial stimulators now FDA-authorized.[13][14]
  5. Magnetic stimulation is a promising non-invasive alternative with growing sham-controlled evidence, particularly for SUI.[8][26][24]
  6. For fecal incontinence, ES is best used as an adjunct to biofeedback rather than monotherapy.[19][20]

Summary​

PFES (intravaginal, transcutaneous, tibial percutaneous / transcutaneous, or extracorporeal magnetic) is a low-risk, reversible adjunct to PFMT and behavioral therapy with a generally favorable safety profile. Modern Cochrane reviews and meta-analyses position PFES as probably better than no treatment but not clearly superior to PFMT. The strongest niches are (a) patients who cannot voluntarily contract pelvic-floor muscles, (b) early post-prostatectomy continence recovery, (c) PTNS for refractory OAB (efficacy comparable to antimuscarinics with fewer AEs), and (d) biofeedback + ES adjunct for fecal incontinence.[1][2][4][13][16][20]

References​

1. Goode PS, Burgio KL, Locher JL, et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. JAMA. 2003;290(3):345-352. doi:10.1001/jama.290.3.345.

2. Stewart F, Berghmans B, Bø K, Glazener CM. Electrical stimulation with non-implanted devices for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017;12:CD012390. doi:10.1002/14651858.CD012390.pub2.

3. Berghmans B, Hendriks E, Bernards A, de Bie R, Omar MI. Electrical stimulation with non-implanted electrodes for urinary incontinence in men. Cochrane Database Syst Rev. 2013;(6):CD001202. doi:10.1002/14651858.CD001202.pub5.

4. Stewart F, Gameiro LF, El Dib R, et al. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev. 2016;12:CD010098. doi:10.1002/14651858.CD010098.pub4.

5. Todhunter-Brown A, Hazelton C, Campbell P, et al. Conservative interventions for treating urinary incontinence in women: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2022;9:CD012337. doi:10.1002/14651858.CD012337.pub2.

6. Yu TY, Yu CY, Escorpizo R, et al. Comparison of nonimplantable electrical stimulation in women with urinary incontinence: a systematic review and network meta-analysis of randomized controlled trials. Sci Rep. 2024;14(1):26957. doi:10.1038/s41598-024-78358-7.

7. Kobashi KC, Vasavada S, Bloschichak A, et al. Updates to surgical treatment of female stress urinary incontinence (SUI): AUA/SUFU guideline (2023). J Urol. 2023;209(6):1091-1098. doi:10.1097/JU.0000000000003435.

8. Yang Z, Liao J, Zhang S, Zhang M, Qiao L. Effectiveness of extracorporeal magnetic stimulation in the treatment of pelvic floor dysfunction: a systematic review and meta-analysis. Neurourol Urodyn. 2025. doi:10.1002/nau.70082.

9. Zomkowski K, Kammers I, Back BBH, et al. The effectiveness of different electrical nerve stimulation protocols for treating adults with non-neurogenic overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2022;33(5):1045-1058. doi:10.1007/s00192-022-05088-7.

10. Lunardi AC, Foltran GC, Carro DF, et al. Efficacy of electrical stimulation in comparison to active training of pelvic floor muscles on stress urinary incontinence symptoms in women: a systematic review with meta-analysis. Disabil Rehabil. 2025;47(13):3256-3267. doi:10.1080/09638288.2024.2419424.

11. Han X, Shen H, Chen J, Wu Y. Efficacy and safety of electrical stimulation for stress urinary incontinence in women: a systematic review and meta-analysis. Int Urogynecol J. 2022;33(4):789-799. doi:10.1007/s00192-021-04928-2.

12. Leonardo K, Seno DH, Mirza H, Afriansyah A. Biofeedback-assisted pelvic floor muscle training and pelvic electrical stimulation in women with overactive bladder: a systematic review and meta-analysis of randomized controlled trials. Neurourol Urodyn. 2022;41(6):1258-1269. doi:10.1002/nau.24984.

13. Xia L, Yan H, Sun Y, et al. Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome. Medicine. 2021;100(45):e27745. doi:10.1097/MD.0000000000027745.

14. Lee UJ, MacDiarmid S, Matthews CA, Gillespie E, Peters KM. Tibial nerve stimulation for urge urinary incontinence and overactive bladder: narrative review of randomized controlled trials and applicability to implantable devices. Adv Ther. 2024;41(7):2635-2654. doi:10.1007/s12325-024-02864-3.

15. Tang G, Liu M, Chen X, et al. Effectiveness of electrical stimulation for treating male urinary incontinence after prostatectomy: a meta-analysis and systematic review. Int J Surg. 2025;111(9):6351-6361. doi:10.1097/JS9.0000000000002685.

16. Zhao L, Yang JW, Wang L, et al. Comparative efficacy of multimodal physical therapies for urinary incontinence after radical prostatectomy: a systematic review and network meta-analysis. Int J Surg. 2025. doi:10.1097/JS9.0000000000004237.

17. Mariotti G, Sciarra A, Gentilucci A, et al. Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. J Urol. 2009;181(4):1788-1793. doi:10.1016/j.juro.2008.11.104.

18. Goode PS, Burgio KL, Johnson TM, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA. 2011;305(2):151-159. doi:10.1001/jama.2010.1972.

19. ACOG Practice Bulletin No. 210: fecal incontinence. Obstet Gynecol. 2019;133(4):e260-e273. doi:10.1097/AOG.0000000000003187.

20. Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev. 2012;(7):CD002111. doi:10.1002/14651858.CD002111.pub3.

21. Mundet L, Rofes L, Ortega O, Cabib C, Clavé P. Kegel exercises, biofeedback, electrostimulation, and peripheral neuromodulation improve clinical symptoms of fecal incontinence and affect specific physiological targets: a randomized controlled trial. J Neurogastroenterol Motil. 2021;27(1):108-118. doi:10.5056/jnm20013.

22. Wald A, Bharucha AE, Limketkai B, et al. ACG clinical guidelines: management of benign anorectal disorders. Am J Gastroenterol. 2021;116(10):1987-2008. doi:10.14309/ajg.0000000000001507.

23. He Q, Xiao K, Peng L, et al. An effective meta-analysis of magnetic stimulation therapy for urinary incontinence. Sci Rep. 2019;9(1):9077. doi:10.1038/s41598-019-45330-9.

24. Lim R, Liong ML, Leong WS, Karim Khan NA, Yuen KH. Pulsed magnetic stimulation for stress urinary incontinence: 1-year followup results. J Urol. 2017;197(5):1302-1308. doi:10.1016/j.juro.2016.11.091.

25. Lukanović D, Antič A, Pavčnik M, et al. Magnetic stimulation in the treatment of urgency urinary incontinence: a randomized sham-controlled clinical trial. Int Urogynecol J. 2025. doi:10.1007/s00192-025-06491-6.

26. Li N, Li L, Zang Y, et al. Rehabilitation effect of magnetic stimulation on female stress urinary incontinence: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2026;173(2):686-697. doi:10.1002/ijgo.70723.

27. Sherman A, Rebullar K, Dmochowski R. A comparison of neuromuscular external stimulator and motion-based sensor devices for the management of urinary incontinence. Expert Rev Med Devices. 2026;23(3):229-234. doi:10.1080/17434440.2026.2626009.

28. Sciarra A, Viscuso P, Arditi A, et al. A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: a meta-analysis and systematic review. Int J Clin Pract. 2021;75(10):e14208. doi:10.1111/ijcp.14208.